Pogátsa G, Dubecz E
Arzneimittelforschung. 1979;29(8):1104-7.
The beta-adrenergic blocking agent propranolol had in itself no notable influence on the blood glucose level in rats, but in combination with chlorpropamide it considerably delayed and enhanced the hypoglycaemic and liver glycogenolysis depressing actions of chlorpropamide. This effect was still more pronounced when the rats were treated in addition to propranolol and chlorpropamide with thyroxine or glanduitrine, which in themselves act as stimulators of liver glycogenolysis. The simultaneous administration of propranolol and chlorpropamide depressed considerably the liver glycogenolysis induced by prolonged fasting and inhibited completely the liver glycogenolysis observed after hepatectomy. The reports available in the literature on propranolol-precipitated hypoglycaemia in patients are surveyed and it is supposed that the beta-adrenergic blocking agent produces hypoglycaemia primarily through the depression of liver glycogenolysis. This observation supports the hypothesis that the adrenergic beta-receptors play an important role in the sympathetic control of liver glycogenolysis.
β-肾上腺素能阻滞剂普萘洛尔本身对大鼠血糖水平无显著影响,但与氯磺丙脲合用时,它会显著延迟并增强氯磺丙脲的降血糖和抑制肝糖原分解的作用。当大鼠除接受普萘洛尔和氯磺丙脲治疗外还接受甲状腺素或垂体后叶素治疗时,这种效应更为明显,甲状腺素和垂体后叶素本身可作为肝糖原分解的刺激剂。同时给予普萘洛尔和氯磺丙脲可显著抑制长时间禁食诱导的肝糖原分解,并完全抑制肝切除术后观察到的肝糖原分解。对文献中关于普萘洛尔诱发患者低血糖的报道进行了综述,并推测β-肾上腺素能阻滞剂主要通过抑制肝糖原分解而产生低血糖。这一观察结果支持了肾上腺素能β受体在交感神经对肝糖原分解的控制中起重要作用的假说。